<DOC>
	<DOCNO>NCT00674583</DOCNO>
	<brief_summary>The purpose study investigate whether GSK Biologicals ' meningococcal vaccine GSK134612 inferior license MenC-CRM197 conjugate vaccine term vaccine antibody response meningococcal serogroup C disease .</brief_summary>
	<brief_title>Comparison GSK Biologicals ' Meningococcal Vaccine ( GSK134612 ) Licensed MenC-CRM197 Vaccine Healthy Children</brief_title>
	<detailed_description>The study 2 study group . One group receive one dose GSK Biologicals ' vaccine GSK 134612 group receive one dose license MenC-CRM197 vaccine . All subject 2 blood sample take : vaccination one month vaccination .</detailed_description>
	<mesh_term>Meningococcal Infections</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Subjects whose parents/guardians , investigator believe comply requirement protocol . A male female , include , 2 10 year age time vaccination . Written inform consent obtain parent ( ) guardian subject . Free obvious health problem establish medical history clinical examination enter study . Previously complete routine childhood vaccination best his/her parents'/guardians ' knowledge . Use investigational nonregistered product ( drug vaccine ) study vaccine within 30 day precede study vaccine dose , plan use study period . Chronic administration immunosuppressant immunemodifying drug within six month prior vaccine dose.. Administration vaccine foreseen study protocol period start one month dose study vaccine end 30 day . Concurrently participate another clinical study plan participation another clinical study , time study period , subject expose investigational noninvestigational product . Previous vaccination meningococcal polysaccharide vaccine serogroup A , C W135 and/or Y ( subject 6 year ) within last five year ( subject 6 year old ) . Previous vaccination meningococcal polysaccharide conjugate vaccine serogroups A , C , W135 and/or Y . History meningococcal disease . Any confirm suspected immunosuppressive immunodeficient condition , include human immunodeficiency virus ( HIV ) infection , base medical history physical examination . A family history congenital hereditary immunodeficiency , immune competence potential vaccine recipient demonstrate . History allergic disease reaction likely exacerbate component vaccine . Major congenital defect serious chronic illness . History neurologic disorder seizure . Acute disease time enrolment Administration immunoglobulins and/or blood product within three month precede study vaccine dose plan administration study period . Exclusion criterion specify region France Subjects contact somebody suffer invasive infection meningococcal serogroups A , C , Y W135 , Subjects live geographic area France local outbreak meningococcal serogroup C occur would thus likely participate vaccination campaign meningococcal serogroup C .</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>10 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Conjugate vaccine</keyword>
	<keyword>Meningococcal disease</keyword>
	<keyword>Immunogenicity</keyword>
	<keyword>Meningococcal vaccine</keyword>
	<keyword>Safety</keyword>
</DOC>